163 related articles for article (PubMed ID: 37959213)
1. The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.
Strobach D; Haimerl L; Mannell H; Stief CG; Karl A; Grimm T; Buchner A
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959213
[TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of the impact of non-oncologic chronic drug therapy on the survival in patients with bladder cancer.
Haimerl L; Strobach D; Mannell H; Stief CG; Buchner A; Karl A; Grimm T
Int J Clin Pharm; 2022 Apr; 44(2):339-347. PubMed ID: 34724148
[TBL] [Abstract][Full Text] [Related]
3. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity.
Tarin TV; Power NE; Ehdaie B; Sfakianos JP; Silberstein JL; Savage CJ; Sjoberg D; Dalbagni G; Bochner BH
Eur Urol; 2012 May; 61(5):1025-30. PubMed ID: 22342773
[TBL] [Abstract][Full Text] [Related]
4. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy.
Bhindi B; Hermanns T; Wei Y; Yu J; Richard PO; Wettstein MS; Templeton A; Li K; Sridhar SS; Jewett MA; Fleshner NE; Zlotta AR; Kulkarni GS
Br J Cancer; 2016 Jan; 114(2):207-12. PubMed ID: 26657651
[TBL] [Abstract][Full Text] [Related]
5. Baseline Health-related Quality of Life Predicts Bladder Cancer-specific Survival Following Radical Cystectomy.
Westhofen T; Eismann L; Buchner A; Schlenker B; Giessen-Jung C; Becker A; Stief CG; Kretschmer A
Eur Urol Focus; 2022 Nov; 8(6):1659-1665. PubMed ID: 35184991
[TBL] [Abstract][Full Text] [Related]
6. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Hermanns T; Bhindi B; Wei Y; Yu J; Noon AP; Richard PO; Bhatt JR; Almatar A; Jewett MA; Fleshner NE; Zlotta AR; Templeton AJ; Kulkarni GS
Br J Cancer; 2014 Jul; 111(3):444-51. PubMed ID: 24918819
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy.
Liu J; Dai Y; Zhou F; Long Z; Li Y; Liu B; Xie D; Tang J; Tan J; Yao K; Zhang Y; Tang Y; He L
Urol Oncol; 2016 Nov; 34(11):484.e1-484.e8. PubMed ID: 27341738
[TBL] [Abstract][Full Text] [Related]
9. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer.
Soria F; Lucca I; Moschini M; Mathieu R; Rouprêt M; Karakiewicz PI; Briganti A; Rink M; Gust KM; Hassler MR; Foerster B; Abufarraj M; Haitel A; Klatte T; Shariat SF
Urol Oncol; 2017 Jun; 35(6):356-362. PubMed ID: 28342660
[TBL] [Abstract][Full Text] [Related]
11. Oncological Outcomes in Patients Treated with Radical Cystectomy for Bladder Cancer: Comparison Between Open, Laparoscopic, and Robot-Assisted Approaches.
Kim TH; Sung HH; Jeon HG; Seo SI; Jeon SS; Lee HM; Choi HY; Jeong BC
J Endourol; 2016 Jul; 30(7):783-91. PubMed ID: 27055782
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy.
Morizawa Y; Miyake M; Shimada K; Hori S; Tatsumi Y; Nakai Y; Anai S; Tanaka N; Konishi N; Fujimoto K
Urol Oncol; 2016 Jun; 34(6):257.e11-7. PubMed ID: 27038696
[TBL] [Abstract][Full Text] [Related]
13. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
[TBL] [Abstract][Full Text] [Related]
14. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Nayan M; Bhindi B; Yu JL; Hermanns T; Mohammed A; Hamilton RJ; Finelli A; Jewett MA; Zlotta AR; Fleshner NE; Kulkarni GS
Urol Oncol; 2015 Sep; 33(9):386.e7-13. PubMed ID: 26097049
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Clinical Utility of Renin-Angiotensin System Inhibitors in Patients Undergoing Radical Surgery for Urothelial Carcinoma of the Upper Urinary Tract.
Yoshida T; Matsuzaki T; Murota T; Kawa G; Matsuda T; Kinoshita H
Clin Genitourin Cancer; 2017 Dec; 15(6):e943-e954. PubMed ID: 28552573
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy.
Koguchi D; Matsumoto K; Shimizu Y; Kobayashi M; Hirano S; Ikeda M; Sato Y; Iwamura M
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918555
[TBL] [Abstract][Full Text] [Related]
17. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.
Mason RJ; Frank I; Bhindi B; Tollefson MK; Thompson RH; Karnes RJ; Tarrell R; Thapa P; Boorjian SA
World J Urol; 2017 Dec; 35(12):1879-1884. PubMed ID: 28913657
[TBL] [Abstract][Full Text] [Related]
18. The occurrence of high-grade complications after radical cystectomy worsens oncological outcomes in patients with bladder cancer.
Yamashita R; Nakamura M; Notsu A; Hashizume A; Shinsaka H; Matsuzazki M; Niwakawa M
Int Urol Nephrol; 2020 Mar; 52(3):475-480. PubMed ID: 31758383
[TBL] [Abstract][Full Text] [Related]
19. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
Gschwend JE; Heck MM; Lehmann J; Rübben H; Albers P; Wolff JM; Frohneberg D; de Geeter P; Heidenreich A; Kälble T; Stöckle M; Schnöller T; Stenzl A; Müller M; Truss M; Roth S; Liehr UB; Leißner J; Bregenzer T; Retz M
Eur Urol; 2019 Apr; 75(4):604-611. PubMed ID: 30337060
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of the systemic immune-inflammation index for patients with bladder cancer after radical cystectomy.
Zhang S; Du J; Zhong X; Tan P; Xu H; Zhang J; Jin D; Li Y; Le W; Xiong X; Lin T; Wei Q
Front Immunol; 2022; 13():1072433. PubMed ID: 36524107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
